ContraFect Corp (NASDAQ:CFRX) Given $2.63 Average Target Price by Analysts
Shares of ContraFect Corp (NASDAQ:CFRX) have received an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $2.63 for the company and are predicting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned ContraFect an industry rank of 74 out of 256 based on the ratings given to related companies.
A number of analysts have weighed in on the company. Chardan Capital reiterated a “buy” rating and set a $1.50 price target on shares of ContraFect in a report on Wednesday, May 15th. Maxim Group assumed coverage on ContraFect in a report on Tuesday. They set a “buy” rating for the company.
ContraFect (NASDAQ:CFRX) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.26. Equities research analysts forecast that ContraFect will post -0.14 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of CFRX. Wells Fargo & Company MN grew its stake in shares of ContraFect by 106.0% in the 1st quarter. Wells Fargo & Company MN now owns 89,287 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 45,935 shares during the period. Hartwell J M Limited Partnership grew its stake in shares of ContraFect by 150.0% in the 1st quarter. Hartwell J M Limited Partnership now owns 100,000 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 60,000 shares during the period. Northern Trust Corp grew its stake in shares of ContraFect by 46.5% in the 4th quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 36,239 shares during the period. Trellus Management Company LLC grew its stake in shares of ContraFect by 43.7% in the 4th quarter. Trellus Management Company LLC now owns 120,676 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 36,721 shares during the period. Finally, Lombard Odier Asset Management USA Corp grew its stake in shares of ContraFect by 66.7% in the 1st quarter. Lombard Odier Asset Management USA Corp now owns 500,000 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 200,000 shares during the period. Hedge funds and other institutional investors own 37.60% of the company’s stock.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Article: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.